vs
EyePoint, Inc.（EYPT）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
Prenetics Global Ltd的季度营收约是EyePoint, Inc.的6.9倍（$4.3M vs $619.0K）
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
EYPT vs PRE — 直观对比
营收规模更大
PRE
是对方的6.9倍
$619.0K
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $619.0K | $4.3M |
| 净利润 | $-67.6M | — |
| 毛利率 | — | 44.9% |
| 营业利润率 | -11364.3% | -396.2% |
| 净利率 | -10922.3% | — |
| 营收同比 | -94.7% | — |
| 净利润同比 | -63.3% | — |
| 每股收益（稀释后） | $-0.82 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EYPTPRE
| Q4 25 | $619.0K | — | ||
| Q3 25 | $966.0K | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $24.5M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $11.7M | — |
净利润EYPTPRE
| Q4 25 | $-67.6M | — | ||
| Q3 25 | $-59.7M | — | ||
| Q2 25 | $-59.4M | — | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $-41.4M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.8M | — | ||
| Q1 24 | $-29.3M | — |
毛利率EYPTPRE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 93.0% | — | ||
| Q2 24 | 85.2% | — | ||
| Q1 24 | 93.5% | — |
营业利润率EYPTPRE
| Q4 25 | -11364.3% | — | ||
| Q3 25 | -6420.8% | — | ||
| Q2 25 | -1166.8% | — | ||
| Q1 25 | -199.7% | — | ||
| Q4 24 | -390.4% | — | ||
| Q3 24 | -311.2% | — | ||
| Q2 24 | -364.5% | — | ||
| Q1 24 | -285.2% | — |
净利率EYPTPRE
| Q4 25 | -10922.3% | — | ||
| Q3 25 | -6183.4% | — | ||
| Q2 25 | -1114.3% | — | ||
| Q1 25 | -184.8% | — | ||
| Q4 24 | -357.3% | — | ||
| Q3 24 | -279.0% | — | ||
| Q2 24 | -325.3% | — | ||
| Q1 24 | -250.6% | — |
每股收益（稀释后）EYPTPRE
| Q4 25 | $-0.82 | — | ||
| Q3 25 | $-0.85 | — | ||
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.65 | — | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $-0.54 | — | ||
| Q2 24 | $-0.58 | — | ||
| Q1 24 | $-0.55 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $306.1M | — |
| 总资产 | $364.0M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EYPTPRE
| Q4 25 | $306.1M | — | ||
| Q3 25 | $204.0M | — | ||
| Q2 25 | $255.7M | — | ||
| Q1 25 | $318.2M | — | ||
| Q4 24 | $370.9M | — | ||
| Q3 24 | $253.8M | — | ||
| Q2 24 | $280.2M | — | ||
| Q1 24 | $299.3M | — |
股东权益EYPTPRE
| Q4 25 | $306.1M | — | ||
| Q3 25 | $200.2M | — | ||
| Q2 25 | $246.0M | — | ||
| Q1 25 | $298.4M | — | ||
| Q4 24 | $336.5M | — | ||
| Q3 24 | $218.7M | — | ||
| Q2 24 | $228.3M | — | ||
| Q1 24 | $249.9M | — |
总资产EYPTPRE
| Q4 25 | $364.0M | — | ||
| Q3 25 | $251.7M | — | ||
| Q2 25 | $301.1M | — | ||
| Q1 25 | $362.6M | — | ||
| Q4 24 | $418.5M | — | ||
| Q3 24 | $300.9M | — | ||
| Q2 24 | $324.2M | — | ||
| Q1 24 | $329.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-66.0M | — |
| 自由现金流率自由现金流/营收 | -10667.7% | — |
| 资本支出强度资本支出/营收 | 159.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-243.4M | — |
8季度趋势，按日历期对齐
经营现金流EYPTPRE
| Q4 25 | $-65.0M | — | ||
| Q3 25 | $-59.4M | — | ||
| Q2 25 | $-62.6M | — | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-35.8M | — | ||
| Q3 24 | $-39.0M | — | ||
| Q2 24 | $-20.2M | — | ||
| Q1 24 | $-31.2M | — |
自由现金流EYPTPRE
| Q4 25 | $-66.0M | — | ||
| Q3 25 | $-60.2M | — | ||
| Q2 25 | $-63.8M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $-40.6M | — | ||
| Q2 24 | $-21.1M | — | ||
| Q1 24 | $-32.4M | — |
自由现金流率EYPTPRE
| Q4 25 | -10667.7% | — | ||
| Q3 25 | -6226.9% | — | ||
| Q2 25 | -1196.5% | — | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | — | ||
| Q3 24 | -385.8% | — | ||
| Q2 24 | -222.4% | — | ||
| Q1 24 | -277.0% | — |
资本支出强度EYPTPRE
| Q4 25 | 159.3% | — | ||
| Q3 25 | 82.6% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 10.2% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
